会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • MODIFIED HEPATITIS C VIRUS PROTEINS
    • 改良型HEPATITIS C病毒蛋白
    • WO2012016290A1
    • 2012-02-09
    • PCT/AU2011/000991
    • 2011-08-04
    • THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTDDRUMMER, HeidiPOUMBOURIOS, PantelisMCCAFFREY, Kathleen
    • DRUMMER, HeidiMCCAFFREY, Kathleen
    • A61K39/29C12N7/00C07K14/02C12Q1/70
    • C07K14/1833A61K39/00A61K39/12C07K14/005C07K16/109C07K2317/76C12N7/00C12N2770/24222C12N2770/24261C12N2770/24262G01N33/56983
    • A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof. A method of producing a composition comprising at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70% monomelic HCV E2 polypeptide, the method comprising expressing a polypeptide in a host cell and isolating the expressed product, wherein the polypeptide is an HCV E2 polypeptide including a receptor binding variant, and wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597.
    • 一种组合物,其包含包含受体结合变体的丙型肝炎病毒(HCV)包膜2(E2)多肽,其中所述多肽被修饰为包含:(i)在2,3或4个半胱氨酸突变或破坏的半胱氨酸,所述半胱氨酸选自C452, C486,C569和C597; 并且其中所述多肽通过分子间二硫键相对于没有半胱氨酸修饰的HCV E2多肽而形成基本上更少的多聚体,并且基本上保留CD81结合; 及其各种用途。 一种制备包含至少40%,或至少45%,或至少50%,或至少55%,或至少60%,或至少65%,或至少70%单体HCV E2的组合物的方法 所述方法包括在宿主细胞中表达多肽并分离所述表达的产物,其中所述多肽是包含受体结合变体的HCV E2多肽,并且其中所述多肽被修饰为包含:(i)在所述多肽中突变或破坏的半胱氨酸 2,3或4个选自C452,C486,C569和C597的半胱氨酸。